VY TRAN: Open Payments
NPI 1801108311 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,120 in 128 payments from 17 companies in 2025. Trend: 2023 $2,594 · 2024 $3,453 · 2025 $5,120
Food & beverage: $3,123Consulting: $1,898Education: $99
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 8 | $1,666 |
| E.R. Squibb & Sons, L.L.C. | 3 | $667 |
| Arcutis Biotherapeutics, Inc. | 27 | $650 |
| Galderma Laboratories, L.P. | 14 | $362 |
| Lilly USA, LLC | 11 | $323 |
| LEO Pharma Inc. | 12 | $224 |
| Janssen Biotech, Inc. | 6 | $221 |
| Incyte Corporation | 10 | $210 |
| UCB, Inc. | 2 | $208 |
| Novartis Pharmaceuticals Corporation | 13 | $199 |
Products named: DUPIXENT, Zoryve, NEMLUVIO, TREMFYA, OPZELURA, Bimzelx, COSENTYX, EBGLYSS.
Industry payments across OK — which companies pay providers there.
